WO2006123676A1 - 角結膜障害の予防または治療剤 - Google Patents
角結膜障害の予防または治療剤 Download PDFInfo
- Publication number
- WO2006123676A1 WO2006123676A1 PCT/JP2006/309797 JP2006309797W WO2006123676A1 WO 2006123676 A1 WO2006123676 A1 WO 2006123676A1 JP 2006309797 W JP2006309797 W JP 2006309797W WO 2006123676 A1 WO2006123676 A1 WO 2006123676A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- corneal
- keratoconjunctivitis
- eye
- administration
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Definitions
- the present invention relates to dry eye, punctate superficial keratopathy, corneal epithelial defect, which contains 2-ferro- 1,2-benzisoselenazol-3 (2H) -one or a salt thereof as an active ingredient
- the present invention relates to a preventive or therapeutic agent for keratoconjunctive disorders such as corneal erosion, corneal ulcer, conjunctival epithelial defect, dry keratoconjunctivitis, upper ring keratoconjunctivitis, filiform keratoconjunctivitis, keratitis, and conjunctivitis.
- the cornea is a transparent avascular tissue having a diameter of about 1 cm and a thickness of about 1 mm
- the conjunctiva is a mucosa covering the surface of the eyeball behind the cornea edge and the back of the eyelid.
- the conjunctiva are known to have important effects on visual function. Corneal and conjunctival disorders caused by various diseases such as corneal ulcer, keratitis, conjunctivitis, and dry eye can be delayed if repair is delayed for some reason or prolonged without repair. Because it is woven, it adversely affects the normal structure of the epithelium, and even the structure and function of the corneal stroma and the endothelium can be impaired.
- Non-Patent Document 1 Non-Patent Document 2
- Non-Patent Document 3 includes 2-Fu-Lu 1, 2-bensisoselenazole-3 (2H).
- ebselen On (generic name: ebselen, hereinafter referred to as “ebselen”) is described to have anti-acidic activity, and in Patent Document 1, ebselen treats cerebral arteriosclerosis and chronic cerebral circulatory disorder It is described that it is effective as an agent.
- Patent Document 1 Japanese Patent Laid-Open No. 2001-261555
- Non-Patent Document 1 Eyesight, 46, 738-743 (1992)
- Non-Patent Document 2 Ophthalmic Surgery, 5, 719-727 (1992)
- Non-Patent Document 3 Proc. Natl. Acad. Sci. USA, 100 (13), 7919-7924 (2003) Disclosure of the Invention
- the inventors of the present invention conducted intensive research to search for a new pharmaceutical use of the above compound, and in a corneal disorder healing efficacy test using a corneal disorder model, the above compound or a salt thereof is corneal.
- the inventors have found that the present invention exerts an excellent preventive and ameliorating effect on obstacles, leading to the present invention.
- Similar to Ebselen a similar test was conducted on known compounds having anti-acidic activity. Ebselen showed a much higher V and effect than those known compounds, and the superior usefulness of Ebselen. It was something to back up.
- the present invention relates to dry eye, punctate superficial keratopathy, corneal epithelial defect, corneal erosion, corneal ulcer, conjunctival epithelial defect, dry keratoconjunctivitis, upper limbal horn containing ebselen or a salt thereof as an active ingredient. It is a prophylactic or therapeutic agent for keratoconjunctival disorders such as conjunctivitis, filiform keratoconjunctivitis, keratitis, and conjunctivitis.
- the ebselen of the present invention is a condensed heterocyclic compound represented by the following chemical structural formula [I]
- the salt of the compound is not particularly limited as long as it is a pharmaceutically acceptable salt, salt with inorganic acid such as hydrochloric acid, nitric acid, sulfuric acid, acetic acid, fumaric acid, maleic acid, succinic acid, tartaric acid. And salts with organic acids such as The above compound may take the form of a solvate.
- inorganic acid such as hydrochloric acid, nitric acid, sulfuric acid, acetic acid, fumaric acid, maleic acid, succinic acid, tartaric acid.
- salts with organic acids such as The above compound may take the form of a solvate.
- the keratoconjunctive disorder refers to a disorder in which the cornea or the conjunctiva is damaged due to various factors such as abnormal tears, metabolic abnormalities, and external injuries, such as dry eye, Examples include punctate superficial keratopathy, corneal epithelial defect, corneal erosion, corneal ulcer, conjunctival epithelial defect, dry keratoconjunctivitis, upper ring keratoconjunctivitis, filiform keratoconjunctivitis, keratitis, conjunctivitis and the like.
- dry eye means tear reduction, dry eye, hypoxia, siedaleren syndrome, dry keratoconjunctivitis, Stevens' Johnson syndrome, lacrimal gland dysfunction, meibomian gland dysfunction, blepharitis , Keratoconjunctival disorders associated with VDT (Visual Display Terminal) work, surgery, drugs, trauma, wearing contour lenses, etc., or symptoms accompanied by keratoconjunctival disorders
- the preventive or therapeutic agent for keratoconjunctival disorders of the present invention can be administered either orally or parenterally (instillation, transdermal, etc.).
- the dosage form include eye drops, eye ointments, skin ointments, injections, tablets, capsules, granules, fine granules, powders and the like. These can be prepared using commonly used techniques.
- eye drops include isotonic agents such as sodium chloride and concentrated glycerin, buffering agents such as sodium phosphate and sodium acetate, polyoxyethylene sorbitan monooleate, polyoxyl stearate 40, polyoxyethylene cured
- a surfactant such as castor oil, a stabilizer such as sodium quenate and sodium edetate, and a preservative such as benzalcolic chloride and noben can be used as necessary.
- the pH should be within the range acceptable for ophthalmic preparations, but is preferably in the range of 4-8.
- the eye ointment can be prepared using a commonly used base such as white petrolatum or liquid paraffin.
- Oral preparations such as tablets, capsules, granules, fine granules and powders are bulking agents such as lactose, crystalline cellulose, starch and vegetable oil, lubricants such as magnesium stearate and talc, hydroxypropylcellulose, Necessary binders such as polybulurpyrrolidone, disintegrating agents such as carboxymethylcellulose calcium and low-substituted hydroxypropylmethylcellulose, coating agents such as hydroxypropylmethylcellulose, macrogol, and silicone resin, and coating agents such as gelatin film And can be prepared accordingly.
- the present invention also provides a keratoconjunctival disorder comprising administering to a patient a pharmacologically effective amount of 2-ferro-1,2-benzisoselenazole-3 (2H) -one or a salt thereof. It relates to preventive or therapeutic methods.
- the dose of the above compound can be appropriately selected depending on symptoms, age, dosage form, etc., but for eye drops, 0.001 to l% (wZv), preferably ⁇ is 0.0001 to 0.1% ( WZV) 1 ⁇ ⁇ ⁇ 1 ⁇ It only needs to be instilled several times.
- wZv 0.001 to l%
- WZV 0.0001 to 0.1%
- 0.1 to 5000 mg per day, preferably 1 to 1000 mg may be administered in a single dose or divided into several doses.
- ebselen exerts an excellent preventive and ameliorating effect in a corneal disorder model. Therefore, dry eye, punctate superficial keratopathy, corneal epithelial defect, corneal erosion It is useful as a preventive or therapeutic agent for keratoconjunctive disorders such as corneal ulcer, conjunctival epithelial defect, dry keratoconjunctivitis, upper ring keratoconjunctivitis, filiform keratoconjunctivitis, keratitis, and conjunctivitis.
- ebselen was administered as follows.
- 3-methyl-1-ferro-2-pyrazolin-5-one represented by the following formula [II] (hereinafter referred to as “edaravone”)
- Dithiolane 3 pentanoic acid (hereinafter referred to as “ex-lipoic acid”?)
- Edaravone and a-lipoic acid are known to have anti-acidic action (J. Radiat. Res., 45, 319-323 (2004), J. Nutr., 133, 3327-3330 (2003))
- ebselen has the same action, and ebselen is common with edaravone and a lipoic acid.
- Ebselen (25 M) in saline solution was instilled into both eyes 6 times a day for 14 days (8 animals per group).
- a saline solution of ⁇ -lipoic acid (200 mg) was instilled into both eyes 6 times a day for 14 days (8 per group).
- the damaged part of the cornea was stained with fluorescein.
- the degree of staining with fluorescein was scored according to the following criteria for each of the upper, middle and lower parts of the cornea, and the improvement rate of corneal damage was calculated from the average of the scores of the respective parts.
- the improvement rate of the ophthalmic group was calculated. This is shown in Table 1.
- the average score is the average of 8 subjects in each group.
- Improvement rate (%) ⁇ (control mouth —) — (administered compound) ⁇ / degree of failure X 100
- ebselen shows a marked improvement rate compared to edarabone and ⁇ -lipoic acid.
- ebselen exhibits a 2-fold improvement over edaravone and alipoic acid, even though it is administered at a 1Z8 fold concentration of edaravone and alipoic acid.
- ebselen has a marked improvement effect on keratoconjunctival disorders.
- SAMP10 develops corneal damage with age. Therefore, 16 Evaluation of corneal injury of female SAMP10 at the age of week was performed, and then administration of ebselen solution or its base was started. The same evaluation was performed again at the age of 24 weeks, 8 weeks after the start of administration. Similarly, corneal damage of female SAMR1 at 16 weeks of age was evaluated, and then the administration of the above-mentioned base was started, and the same evaluation was performed again at 24 weeks of age, 8 weeks after the start of administration.
- a 1% (WZV) aqueous solution of methylcellulose was orally administered to SAMP 10 in the same manner at a rate of 6.67 L / lg of mouse body weight.
- 1% (WZV) methylcellulose aqueous solution was orally administered to female SAMR1, which is a control animal.
- the number of cases in each group of SAMP10 is 22 eyes (11 animals), and the number of SAMR1 cases is 16 eyes (8 animals).
- SAMP 10 and SAMR 1 cornea lesions were stained with fluorescein immediately before and 8 weeks after the start of administration.
- the degree of staining with fluorescein was determined based on the criteria described in ⁇ 1.
- Table 2 shows the fluorescein staining scores for SAMP10 and SAMR1 at 16 and 24 weeks of age.
- surface is a mean average error in each group.
- Sterilized purified water By changing the amount of added ebselen, the concentration is 0.001% (wZv), 0.03% (w / v), 0.1% (WZV), 0.3% (w / v), 1. 0% (wZv) eye drops can be prepared.
- the concentration of 0.05% (w / v), 0.3% (w / v), 0.5% (w / v), 1% (w / v) Eye drops can be prepared.
- eye ointments with concentrations of 1% (w / w) and 3% (w / w) can be prepared.
- Ebselen and lactose are mixed in a blender, and carboxymethylcellulose calcium and hydroxypropylcellulose are mixed therein, the mixture is granulated, and the resulting granules are dried. After drying, the mixture is granulated, and magnesium stearate is mixed in the granulated granule and mixed, and the mixture is compressed with a tableting machine. Also, by changing the amount of ebselen added, tablets with a content of 0.1 mg, 10 mg, and 50 mg in lOOmg can be prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2608457A CA2608457C (en) | 2005-05-17 | 2006-05-17 | Ebselen as a prophylactic or therapeutic agent for corneal or conjunctival disorders |
DK06746500.5T DK1884234T3 (da) | 2005-05-17 | 2006-05-17 | Profylaktisk eller terapeutisk middel til korneale og konjunktivale lidelser |
ES06746500T ES2389566T3 (es) | 2005-05-17 | 2006-05-17 | Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva |
EP06746500A EP1884234B1 (en) | 2005-05-17 | 2006-05-17 | Prophylactic or therapeutic agent for corneal and conjunctival disorder |
US11/920,477 US8222283B2 (en) | 2005-05-17 | 2006-05-17 | Method for treating a keratoconjunctival disorder |
CN2006800171140A CN101175487B (zh) | 2005-05-17 | 2006-05-17 | 依布硒啉的制药用途 |
SI200631399T SI1884234T1 (sl) | 2005-05-17 | 2006-05-17 | Profilaktično ali terapevtsko sredstvo za kornealno in konjunktivalno motnjo |
KR1020077026576A KR101286883B1 (ko) | 2005-05-17 | 2006-05-17 | 각결막 장애의 예방 또는 치료제 |
PL06746500T PL1884234T3 (pl) | 2005-05-17 | 2006-05-17 | Środek profilaktyczny lub leczniczy w zaburzeniach rogówkowych i spojówkowych |
NO20076398A NO20076398L (no) | 2005-05-17 | 2007-12-11 | Preventivt eller terapeutisk middel for keratokonjunktive forstyrrelser |
US13/479,485 US8536207B2 (en) | 2005-05-17 | 2012-05-24 | Method for treating a keratoconjunctival disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005143477 | 2005-05-17 | ||
JP2005-143477 | 2005-05-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/920,477 A-371-Of-International US8222283B2 (en) | 2005-05-17 | 2006-05-17 | Method for treating a keratoconjunctival disorder |
US13/479,485 Continuation US8536207B2 (en) | 2005-05-17 | 2012-05-24 | Method for treating a keratoconjunctival disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006123676A1 true WO2006123676A1 (ja) | 2006-11-23 |
Family
ID=37431248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/309797 WO2006123676A1 (ja) | 2005-05-17 | 2006-05-17 | 角結膜障害の予防または治療剤 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8222283B2 (ja) |
EP (1) | EP1884234B1 (ja) |
KR (1) | KR101286883B1 (ja) |
CN (1) | CN101175487B (ja) |
CA (1) | CA2608457C (ja) |
CY (1) | CY1113161T1 (ja) |
DK (1) | DK1884234T3 (ja) |
ES (1) | ES2389566T3 (ja) |
NO (1) | NO20076398L (ja) |
PL (1) | PL1884234T3 (ja) |
PT (1) | PT1884234E (ja) |
RU (1) | RU2406499C2 (ja) |
SI (1) | SI1884234T1 (ja) |
WO (1) | WO2006123676A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009107759A1 (ja) | 2008-02-28 | 2009-09-03 | 参天製薬株式会社 | 視神経障害を伴う眼疾患の予防又は治療剤 |
US8222283B2 (en) | 2005-05-17 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Method for treating a keratoconjunctival disorder |
US8309612B2 (en) | 2007-05-25 | 2012-11-13 | Santen Pharmaceutical Co., Ltd. | Method for treating age-related macular degeneration |
GB2550110A (en) * | 2016-04-28 | 2017-11-15 | Univ Oxford Innovation Ltd | Treatment of impulsivity-related disorders |
US11707453B2 (en) | 2017-10-26 | 2023-07-25 | Oxford University Innovation Limited | Treatment of unipolar depressive disorder |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2459615C1 (ru) * | 2011-03-05 | 2012-08-27 | Илья Александрович Марков | Глазные капли для лечения болезни сухого глаза |
EP2783689B1 (en) | 2011-11-24 | 2019-09-25 | Toyo Sugar Refining Co., Ltd. | Keratoconjunctival protecting agent, or keratoconjunctival disorder inhibiting agent |
RU2522381C1 (ru) * | 2013-01-24 | 2014-07-10 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения трофических эрозий роговицы |
KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
RU2544225C1 (ru) * | 2013-12-13 | 2015-03-10 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения послеоперационных эрозий роговицы после удаления птеригиума |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
CN108024831A (zh) | 2015-10-23 | 2018-05-11 | 纽约市哥伦比亚大学理事会 | 由激光诱导的组织中的胶原交联 |
WO2017214604A1 (en) | 2016-06-10 | 2017-12-14 | The Trustees Of Columbia University In The City Of New York | Devices, methods, and systems for detection of collagen tissue features |
US11554104B2 (en) | 2017-08-18 | 2023-01-17 | The Schepens Eye Research Institute, Inc. | Compositions for the treatment of dry eye and methods of use thereof |
US11666481B1 (en) | 2017-12-01 | 2023-06-06 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of collagen-containing tissues |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10511404A (ja) * | 1995-10-26 | 1998-11-04 | ロレアル | 敏感肌の治療における少なくとも1つのnoシンターゼ阻害剤の使用 |
JPH11507669A (ja) * | 1995-06-12 | 1999-07-06 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ−2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療 |
JP2001510468A (ja) * | 1996-12-27 | 2001-07-31 | オクシス アイル オブ マン,リミテッド | 環状有機セレン化合物、その製造及びその使用 |
JP2004512287A (ja) * | 2000-10-24 | 2004-04-22 | メルク サンテ | 糖尿病性網膜症の予防または処置のための網膜細胞アポトーシス抑制剤の使用 |
JP2006104199A (ja) * | 2004-09-13 | 2006-04-20 | Santen Pharmaceut Co Ltd | 角結膜障害治療剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3616923A1 (de) | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
US4778814A (en) | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one |
JP2001261555A (ja) | 2000-03-17 | 2001-09-26 | Dai Ichi Seiyaku Co Ltd | 脳動脈中膜肥厚抑制剤 |
TWI263505B (en) * | 2001-11-19 | 2006-10-11 | Sucampo Ag | Pharmaceutical composition comprising a C1C-2 channel opener |
WO2004069157A2 (en) * | 2003-01-17 | 2004-08-19 | Ophthalmic Research Associates, Inc. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
WO2004071419A2 (en) | 2003-02-07 | 2004-08-26 | The General Hospital Corporation | Methods and compositions for modulating glutamate transport activity in the nervous system |
RU2406499C2 (ru) | 2005-05-17 | 2010-12-20 | Сантен Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений |
JP2008013448A (ja) | 2006-07-03 | 2008-01-24 | Gifu Prefecture | 視神経細胞保護剤 |
ES2370751T3 (es) | 2007-05-25 | 2011-12-22 | Santen Pharmaceutical Co., Ltd | Agente profiláctico o terapéutico para la degeneración macular asociada a la edad. |
KR20100124756A (ko) | 2008-02-28 | 2010-11-29 | 산텐 세이야꾸 가부시키가이샤 | 시신경 장해를 동반하는 안질환의 예방 또는 치료제 |
-
2006
- 2006-05-17 RU RU2007146688/15A patent/RU2406499C2/ru not_active IP Right Cessation
- 2006-05-17 EP EP06746500A patent/EP1884234B1/en not_active Not-in-force
- 2006-05-17 CN CN2006800171140A patent/CN101175487B/zh not_active Expired - Fee Related
- 2006-05-17 DK DK06746500.5T patent/DK1884234T3/da active
- 2006-05-17 WO PCT/JP2006/309797 patent/WO2006123676A1/ja active Application Filing
- 2006-05-17 PL PL06746500T patent/PL1884234T3/pl unknown
- 2006-05-17 PT PT06746500T patent/PT1884234E/pt unknown
- 2006-05-17 ES ES06746500T patent/ES2389566T3/es active Active
- 2006-05-17 KR KR1020077026576A patent/KR101286883B1/ko not_active IP Right Cessation
- 2006-05-17 CA CA2608457A patent/CA2608457C/en not_active Expired - Fee Related
- 2006-05-17 US US11/920,477 patent/US8222283B2/en not_active Expired - Fee Related
- 2006-05-17 SI SI200631399T patent/SI1884234T1/sl unknown
-
2007
- 2007-12-11 NO NO20076398A patent/NO20076398L/no not_active Application Discontinuation
-
2012
- 2012-05-24 US US13/479,485 patent/US8536207B2/en not_active Expired - Fee Related
- 2012-09-28 CY CY20121100898T patent/CY1113161T1/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11507669A (ja) * | 1995-06-12 | 1999-07-06 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ−2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療 |
JPH10511404A (ja) * | 1995-10-26 | 1998-11-04 | ロレアル | 敏感肌の治療における少なくとも1つのnoシンターゼ阻害剤の使用 |
JP2001510468A (ja) * | 1996-12-27 | 2001-07-31 | オクシス アイル オブ マン,リミテッド | 環状有機セレン化合物、その製造及びその使用 |
JP2004512287A (ja) * | 2000-10-24 | 2004-04-22 | メルク サンテ | 糖尿病性網膜症の予防または処置のための網膜細胞アポトーシス抑制剤の使用 |
JP2006104199A (ja) * | 2004-09-13 | 2006-04-20 | Santen Pharmaceut Co Ltd | 角結膜障害治療剤 |
Non-Patent Citations (3)
Title |
---|
DATABASE BIOSIS [online] RUMI I. ET AL.: "Studies on ocular pharmacology (Rept.32): Beneficial effect of EPC-1, a novel antioxidant, on allergic conjunctivitis and peroxynitrite-induced increase in microvascular permeability in guinea pigs", XP003004150, Database accession no. (PREV200000222389) * |
HURST J.S. ET AL.: "Effects of ebselen on arachidonate metabolism by ocular and nonocular tissues", BIOCHEMICAL PHARMACOLOGY, vol. 38, no. 19, 1989, pages 3357 - 3363, XP000852930 * |
JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. SUPPL. 1, 2000, pages 273P * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8222283B2 (en) | 2005-05-17 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Method for treating a keratoconjunctival disorder |
US8536207B2 (en) | 2005-05-17 | 2013-09-17 | Santen Pharmaceutical Co., Ltd. | Method for treating a keratoconjunctival disorder |
US8309612B2 (en) | 2007-05-25 | 2012-11-13 | Santen Pharmaceutical Co., Ltd. | Method for treating age-related macular degeneration |
WO2009107759A1 (ja) | 2008-02-28 | 2009-09-03 | 参天製薬株式会社 | 視神経障害を伴う眼疾患の予防又は治療剤 |
GB2550110A (en) * | 2016-04-28 | 2017-11-15 | Univ Oxford Innovation Ltd | Treatment of impulsivity-related disorders |
US10653680B2 (en) | 2016-04-28 | 2020-05-19 | Oxford University Innovation Limited | Treatment of impulsivity-related disorders |
US11707453B2 (en) | 2017-10-26 | 2023-07-25 | Oxford University Innovation Limited | Treatment of unipolar depressive disorder |
Also Published As
Publication number | Publication date |
---|---|
PT1884234E (pt) | 2012-07-26 |
ES2389566T3 (es) | 2012-10-29 |
RU2007146688A (ru) | 2009-06-27 |
EP1884234B1 (en) | 2012-07-18 |
KR20080016556A (ko) | 2008-02-21 |
US8222283B2 (en) | 2012-07-17 |
CN101175487A (zh) | 2008-05-07 |
CA2608457A1 (en) | 2006-11-23 |
DK1884234T3 (da) | 2012-10-08 |
CY1113161T1 (el) | 2016-04-13 |
RU2406499C2 (ru) | 2010-12-20 |
PL1884234T3 (pl) | 2012-11-30 |
US8536207B2 (en) | 2013-09-17 |
NO20076398L (no) | 2008-02-11 |
CA2608457C (en) | 2013-09-10 |
US20120232119A1 (en) | 2012-09-13 |
SI1884234T1 (sl) | 2012-10-30 |
CN101175487B (zh) | 2011-11-16 |
EP1884234A1 (en) | 2008-02-06 |
EP1884234A4 (en) | 2010-01-13 |
KR101286883B1 (ko) | 2013-07-16 |
US20090105313A1 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006123676A1 (ja) | 角結膜障害の予防または治療剤 | |
JP4217832B2 (ja) | 角結膜障害の治療剤 | |
JP5314931B2 (ja) | 加齢黄斑変性の予防又は治療剤 | |
EP2119440A1 (en) | Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease | |
JP5087233B2 (ja) | 角結膜障害の予防または治療剤 | |
JP4922588B2 (ja) | 角結膜障害治療剤 | |
JPH10218792A (ja) | アンギオテンシン変換酵素阻害薬を有効成分とする涙液分泌促進および角結膜障害治療剤 | |
WO2007148744A1 (ja) | フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤 | |
RU2423127C2 (ru) | Терапевтическое средство против роговично-конъюнктивального нарушения | |
US20080070958A1 (en) | Therapeutic Agent for Keratoconjunctival Disorder | |
US20030007959A1 (en) | Oral methods of treatment | |
US20240261273A1 (en) | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease | |
JP2006104199A (ja) | 角結膜障害治療剤 | |
WO2005039571A1 (ja) | 角結膜障害治療剤 | |
JP2007291091A (ja) | 角結膜障害治療剤 | |
WO2005108396A1 (ja) | 角結膜障害治療剤 | |
WO2007114315A1 (ja) | 角結膜障害治療剤 | |
JP2007182435A (ja) | 角結膜障害治療剤 | |
JP2008024699A (ja) | フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680017114.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2608457 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11920477 Country of ref document: US Ref document number: 1020077026576 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006746500 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007146688 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006746500 Country of ref document: EP |